Quick, easy, color-coded technique will speed identification of drugs for diseases

March 22, 2001

John Hopkins researchers have developed the first color-coded tracking system to see how receptors on the surface of a living cell transmit signals to the cell's interior and regulate a wide range of biological processes. The technology, described in the March 23 issue of Science, should significantly speed up the search for drugs needed to treat heart disease, cancer, asthma and other ailments.

"For the first time, we can actually see the activation of GPCRs, receptors that set off many cascades in a cell," says Peter Devreotes, Ph.D., director of the Department of Cell Biology and Anatomy at Hopkins and principal investigator of the study. "Instead of having to screen for effective drugs by estimating their secondary chemical effects, we can see the action directly on the receptor."

A vast family of GPCRs, or G-protein coupled receptors, trigger changes within cells when set off by hormones, neurotransmitters, chemoattractants and other proteins. Researchers have known that an inactivated GPCR holds onto three G-protein pieces (alpha, beta and gamma) that dangle into the interior of the cell. When a molecule activates and binds to a receptor's "docking bay" on the outside of the cell, the receptor causes the three pieces to drift apart.

Devreotes and his colleagues created analog proteins that mimic the alpha and beta forms and tagged them with fluorescent proteins. The researchers hoped these markers would be so close together that a process known as FRET (fluorescence resonance energy transfer) would occur and they would fluoresce yellow. If the receptors were activated, these tags would drift apart and they would show up as cyan under the microscope.

Using a one-celled amoeba called Dictyostelium, whose GPCRs serve as docking bays for a chemical known as cyclic AMP (cAMP), the researchers added alpha and beta analogs to the genome of the amoeba and then exposed the cells to cAMP. When the GPCR was inactive, it emitted yellow light, when activated, it turned cyan.

"Half of all drug targets involve GPCR-linked signaling pathways. This technology could be used to screen for chemicals that bind GPCRs and hasten the discovery of drugs that neutralize them," says Chris Janetopoulos, Ph.D., a postdoctoral fellow in the Department of Cell Biology and Anatomy and lead author of the paper.

The researchers are now testing their color-coding technique on mammalian cells, and early results are encouraging. They are also using this technique to explore the mechanisms that amoeba use to move directionally. For more information on Devreotes' research, visit his lab at http://www.med.jhu.edu/devreotes/.

In addition to Devreotes and Janetopoulos, Tian Jin from Hopkins also contributed to this study. The study was funded by the National Institutes of Health and an American Cancer Society fellowship to Janetopoulos.
-end-
Johns Hopkins Medical Institutions' news releases are available on an EMBARGOED basis on EurekAlert at http://www.eurekalert.org, Newswise at http://www.newswise.com and from the Office of Communications and Public Affairs' direct e-mail news release service. To enroll, call 410-955-4288 or send e-mail to bsimpkins@jhmi.edu.

On a POST-EMBARGOED basis find them at http://www.hopkinsmedicine.org, Quadnet at http://www.quad-net.com and ScienceDaily at http://www.sciencedaily.com.

Media Contact: Kate O'Rourke 410-955-8665
Email: korourke@jhmi.edu

Johns Hopkins Medicine

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.